BZYR.OTC.PinkBurzynski Research Institute INC

10-Q: Burzynski Research Institute Reports Net Loss for Q3 2024 Amid Ongoing Clinical Hold

Sentiment:

Quarterly Report 13 January 2025 4:16 PM

📋All filings for Burzynski Research Institute INC

Burzynski Research Institute's Q3 2024 financial results reveal a net loss, with research and development expenses increasing and a clinical hold still in effect.

Delay expectedThe company's IND 43742 remains under a full clinical hold by the FDA, preventing the enrollment of new patients in clinical trials.

Worse than expectedThe company reported a net loss for both the three and nine months ended November 30, 2024.Research and development expenses increased for both the three and nine months ended November 30, 2024.The company's IND 43742 remains under a full clinical hold by the FDA.

Summary

Burzynski Research Institute, Inc. reported its financial results for the third quarter of 2024.
The company is primarily engaged in research and development of Antineoplaston drugs for cancer treatment.
The company's investigational new drug application (IND) 43742 remains under a full clinical hold by the FDA, preventing the enrollment of new patients in clinical trials.
For the three months ended November 30, 2024, the company reported a net loss of $352,239, compared to a net loss of $433,015 for the same period in 2023.
Research and development expenses increased to $301,183 from $218,069 year-over-year.
General and administrative expenses decreased to $51,056 from $214,946 year-over-year.
For the nine months ended November 30, 2024, the company reported a net loss of $1,093,409, compared to a net loss of $972,524 for the same period in 2023.
Research and development costs increased to $804,447 from $614,240 year-over-year.
General and administrative expenses decreased to $288,962 from $358,284 year-over-year.
The company's operations are primarily funded by contributions from Dr. Burzynski, who also provides laboratory and research space.
The Research Funding Agreement with Dr. Burzynski has been renewed until February 28, 2025.
The company estimates spending approximately $300,000 during the remaining quarter of the fiscal year ending February 28, 2025.
The company is economically dependent on funding from Dr. Burzynski's medical practice.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the ongoing clinical hold, net losses, and reliance on a single funding source. While there are some positive aspects like decreased administrative expenses, the overall outlook is concerning.

Positives

General and administrative expenses decreased for both the three and nine months ended November 30, 2024, indicating improved cost management.
The Research Funding Agreement with Dr. Burzynski has been renewed, ensuring continued funding for the company's operations until February 28, 2025.

Negatives

The company reported a net loss for both the three and nine months ended November 30, 2024.
Research and development expenses increased for both the three and nine months ended November 30, 2024.
The company's IND 43742 remains under a full clinical hold by the FDA, preventing the enrollment of new patients in clinical trials.
The company is economically dependent on funding from Dr. Burzynski's medical practice, creating a significant risk if this funding is disrupted.

Risks

The full clinical hold by the FDA on IND 43742 prevents the enrollment of new patients and hinders the company's research progress.
The company's economic dependence on Dr. Burzynski's funding poses a significant risk to its operations.
There is no assurance that Dr. Burzynski will be able to continue funding the company's operations.
The company may be required to seek additional capital through equity or debt financing, but there is no assurance that it will be able to raise such capital on acceptable terms.
There is no assurance that the company will ever achieve positive operating cash flow.
The company is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.

Future Outlook

The company estimates that it will spend approximately $300,000 during the remaining quarter of the fiscal year ending February 28, 2025, and anticipates continued funding from Dr. Burzynski, although there is no assurance of this.

Industry Context

Burzynski Research Institute operates in the pharmaceutical research and development sector, specifically focusing on cancer treatment. The company's reliance on a single individual for funding and the ongoing clinical hold present significant challenges compared to more diversified and commercially successful pharmaceutical companies.

Comparison to Industry Standards

Burzynski Research Institute's financial situation, marked by consistent net losses and reliance on a single funding source, contrasts sharply with industry leaders like Pfizer or Roche, which have diversified revenue streams and approved products.
The ongoing clinical hold on IND 43742 is a significant deviation from the norm, as successful biotech companies typically progress through clinical trials and achieve regulatory approvals.
Unlike companies such as Moderna or BioNTech, which have successfully commercialized novel therapies, Burzynski Research Institute has not yet achieved FDA approval for its Antineoplaston drugs.
The company's research and development expenses, while increasing, are significantly lower than those of larger pharmaceutical companies, reflecting its limited resources and scope of operations.
The company's dependence on Dr. Burzynski's funding model is atypical compared to the venture capital or public market funding strategies employed by most biotech firms.

Related Party Transactions

Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception.
The Company entered into a Research Funding Agreement with Dr. Burzynski, pursuant to which the Company agreed to undertake all scientific research in connection with the development of new or improved Antineoplastons for the treatment of cancer and Dr. Burzynski agreed to fund the Company's Antineoplaston research for that purpose.
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. are reported as research and development costs and as additional paid-in capital.

Stakeholder Impact

Shareholders face continued uncertainty due to the company's financial losses and regulatory challenges.
Employees' job security is dependent on the company's ability to secure funding and advance its research programs.
Patients seeking treatment with Antineoplaston drugs are impacted by the clinical hold, which prevents new patients from enrolling in clinical trials.
The company's suppliers and creditors face potential risks due to its financial instability.

Next Steps

The company needs to address the deficiencies identified by the FDA to lift the clinical hold on IND 43742.
The company needs to secure continued funding from Dr. Burzynski or explore alternative funding sources.
The company needs to continue its research and development efforts to advance its Antineoplaston drugs towards FDA approval.

Key Dates

Date	Description
September 14, 1996	The Company granted 600,000 stock options to an officer who is no longer with the Company.
March 1, 1997	The Company entered into a Research Funding Agreement with Dr. Burzynski.
September 3, 2004	The FDA granted the Company's request for orphan drug designation (ODD) for the Company's Antineoplastons (A10 & AS2-1 Antineoplaston) for treatment of patients with brain stem glioma.
October 30, 2008	The FDA granted the Company's request for ODD for Antineoplastons (A10 and AS2-1 Antineoplaston) for the treatment of gliomas.
January 13, 2009	The Company announced that the Company had reached an agreement with the FDA for the Company to move forward with a pivotal Phase III clinical trial of combination Antineoplaston therapy plus radiation therapy in patients with newly diagnosed diffuse, intrinsic brainstem gliomas (DBSG).
June 25, 2012	The Company informed the FDA of a serious adverse event in which a patient who was receiving Antineoplastons developed grade 4 hypernatremia and subsequently died.
July 30, 2012	The FDA placed a partial clinical hold for enrollment of new pediatric patients under single patient protocols or in any of the active Phase II or Phase III studies under IND 43742.
January 9, 2013	The FDA notified the Company that the agency was placing IND 43742 on partial clinical hold, due to a lack of a complete response to the issues raised by the FDA and what the FDA deemed a misleading, erroneous, and incomplete investigator brochure.
June 20, 2014	After several amendments to the IND which were reviewed by the FDA, the FDA concluded that BT-52 can be initiated and the partial clinical hold was removed by the FDA.
February 4, 2015	The Company received IRB approval for FDA reviewed protocol BT-55 open label, Phase II study of Antineoplaston A10 and AS2-1 in patients with a Diffuse Intrinsic Brainstem Glioma (DIPG) in five treatment groups based on patients age and prior treatment.
April 20, 2016	The Company received a full clinical hold letter from the FDA based on FDA's inspection of S.R. Burzynski's manufacturing facility in March 2015.
May 17, 2016	A temporary restraining order from the US District Court of Rhode Island allowed the resumption of patient #1's Antineoplaston therapy.
May 26, 2016	A subsequent letter from the FDA informed the Company that the full clinical hold was replaced and a partial clinical hold was imposed.
June 14, 2016	The FDA issued a letter to the Company in connection with the FDA's inspection of S.R. Burzynski's manufacturing facility (the SRB Manufacturing) in March 2015.
February 20, 2017	BRI informed the FDA of the death of patient #1 on February 19, 2017.
August 24, 2017	The FDA imposed a full clinical hold on IND 43742 until deficiencies regarding the SRB Manufacturing are resolved.
July 2, 2019	The Original License Agreement between the Company and Dr. Burzynski terminated upon the expiration of the last patent licensed to the Company under such agreement.
May 22, 2023	The Company entered into a new License Agreement (the New License Agreement) with Dr. Burzynski.
February 28, 2025	The Research Funding Agreement with Dr. Burzynski has been renewed until this date.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.